Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 8/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 8/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 8/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 3/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 3/20 | 1.00 |
| ▸ | GRIK3 | Q13003 | 3/20 | 1.00 |
| ▸ | GRIK4 | Q16099 | 3/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GRM6 | O15303 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nbqx SCHEMBL29356960 | 1.00 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| Nbqx SCHEMBL2487669 | 0.99 | GRIA1 (0.98) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| Nbqx SCHEMBL3681836 | 0.99 | GRIA1 (0.98) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3678511 | 0.90 | GRIA1 (0.82) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL30389920 | 0.88 | GRIA1 (0.78) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3682827 | 0.86 | GRIA1 (0.75) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3670356 | 0.84 | GRIA1 (0.72) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3683483 | 0.80 | KMT2A (0.67) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3676464 | 0.80 | GRIA1 (0.67) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3691418 | 0.79 | KMT2A (0.65) | GRIA1GRIA2GRIA3GRIA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251627-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | ZYMO RESEARCH CORPORATION (US) | 2022-08-11 | — | — | US | claimed |
| EP-3989722-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | Zymo Research Corporation (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2020264313-A1 | COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF | ZYMO RESEARCH CORPORATION (US) | 2020-12-30 | — | — | WO | claimed |
| JP-2012500283-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110244486-A1 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | PEREGO, CARLA (IT) | 2011-10-06 | — | — | US | claimed |
| EP-2366106-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | Perego, Carla (IT) | 2011-09-21 | — | — | EP | claimed |
| US-20110190356-A1 | Compositions and Methods of Using (R)- Pramipexole | KNOPP NEUROSCIENCES INC. (US) | 2011-08-04 | — | — | US | claimed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2334185-A1 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE | Knopp Neurosciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010057647-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2010-05-27 | — | — | WO | claimed |
| WO-2010022140-A1 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE | KNOPP NEUROSCIENCES, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-1270002-B1 | Pharmaceutical compositions for preventing problem behaviour of companion animals | AJINOMOTO KK (JP) | 2004-09-15 | — | — | EP | claimed |
| EP-1138332-B1 | Treatment of poriomania | AJINOMOTO KK (JP) | 2004-06-09 | — | — | EP | claimed |
| US-6191132-B1 | THERAPY FOR PARKINSON'S DISEASE; SYNERGISTIC MIXTURE WITH ANTIDOPAMINE AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | claimed |
| EP-0516795-B1 | MEDICAMENTS CONTAINING A QUISQUALATE RECEPTOR ANTAGONIST AND A DOPAMINE AGONIST FOR THE TREATMENT OF PARKINSON'S DISEASE | SCHERING AG (DE) | 1999-05-26 | — | — | EP | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3464342-B1 | MUTANT LIGHT-INDUCIBLE ION CHANNEL OF CHRIMSON | MAX PLANCK GESELLSCHAFT (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-5385903-A | Pharmaceutical agent for treatment of withdrawal symptoms | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-31 | — | — | US | disclosed |
| EP-0516795-A1 | USE OF QUISQUALATE-RECEPTOR ANTAGONISTS FOR TREATING PARKINSON'S DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-09 | — | — | EP | disclosed |
| WO-1992011012-A1 | USE OF QUISQUALATE-RECEPTOR ANTAGONISTS FOR TREATING PARKINSON'S DISEASE | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | GRIA1 1312/4885GRIA2 1365/4885GRIA3 1422/4885 |
| US-20110190356-A1 | Compositions and Methods of Using (R)- Pramipexole | HSPE1, GRIN2B, GRIN2A | GRIA1 181/4885GRIA2 230/4885GRIA3 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.